AP NEWS

Chronic Heart Failure Drug Development Pipeline Analysis 2018 - Companies, Drugs, Clinical Trials and Latest Developments in the Chronic Heart Failure Market - ResearchAndMarkets.com

July 12, 2018

DUBLIN--(BUSINESS WIRE)--Jul 12, 2018--The “2018 Chronic Heart Failure Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Chronic Heart Failure Market” report has been added to ResearchAndMarkets.com’s offering.

The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Chronic Heart Failure pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Chronic Heart Failure pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Key Topics Covered:

1 Chronic Heart Failure Pipeline Analysis

2 Chronic Heart Failure - Company Wise Pipeline Analysis

3 Chronic Heart Failure R&D Pipeline Snapshots

4 Recent Developments in Chronic Heart Failure Pipeline

5 Appendix

Companies Featured

AETAS Pharma Co.,Ltd. Amgen Inc. ARCA biopharma Inc Armgo Pharma, Inc. AstraZeneca Plc Bayer AG Boehringer Ingelheim GmbH Bristol-Myers Squibb Co Capricor Therapeutics, Inc. Celyad SA Juventas Therapeutics, Inc. Servier Laboratories Limited Mast Therapeutics, Inc. Mesoblast Limited Novartis International AG Pfizer Inc. Pierre Fabre S.A. Quantum Genomics SA scPharmaceuticals Inc Stemedica Cell Technologies, Inc. Theravance Biopharma, Inc. Trio Medicines Ltd Vifor pharma Group Zensun (Shanghai) Sci & Tech Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/research/rfjq5h/chronic_heart?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180712005412/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Cardiovascular Drugs ,Clinical Trials

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/12/2018 08:05 AM/DISC: 07/12/2018 08:06 AM

http://www.businesswire.com/news/home/20180712005412/en

AP RADIO
Update hourly